A pill that doubles life expectancy in patients with pancreatic cancer has been hailed as the biggest breakthrough for ...
The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.
KLAS Las Vegas on MSN
Cure 4 The Kids Foundation honors record graduating class
Cure 4 The Kids Foundation is honoring its largest graduating class ever, 49 patients who are finishing high school on time ...
A new daily pill called daraxonrasib is showing promise against advanced pancreatic cancer in a first-in-human trial of 168 patients with RAS mutations.
An experimental pancreatic cancer drug that’s been shown to double survival in patients with advanced stages of the disease is poised to revolutionize the way the cancer is treated, oncologists say.
The trial is part of a larger trend towards targeted chemotherapies, Santin says, many of which may come onto the market in the next few decades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results